New drugs, big spending: Cancer DTC spend surges to $500M by Beth Snyder Bulik Monday, June 4, 2018 Just how big has the wave of new cancer drug ads been? Syneos analyzed DTC data from the past decade to find out.
No need for a megamerger, Pfizer CEO says. Our pipeline's got it by Eric Sagonowsky Tuesday, May 1, 2018 Pfizer CEO Ian Read contends that the company's pipeline is strong enough to fuel growth. In other words, don't look for a "transformative" deal.
Lilly highlights 'relentless' women in ads for breast cancer med by Beth Snyder Bulik Wednesday, April 18, 2018 Eli Lilly’s first oncology campaign launched last week, putting the drugmaker on a growing list of pharma companies running DTC ads for cancer drugs.
Pfizer's Ibrance joins February's TV ad-spending leaders by Beth Snyder Bulik Friday, March 23, 2018 Debut ads helped drive list-toppers for pharma TV spend in February, with Ibrance, Otezla, Rexulti, Entresto and Eliquis entering the top 10.
Lilly nabs another approval for third-to-the-party Verzenio by Carly Helfand Tuesday, February 27, 2018 It’s been only five months since Lilly breast cancer drug Verzenio launched, but it just racked up its third approval in a competitive market.
Novartis grabs Kisqali 'breakthrough' in younger women by Carly Helfand Friday, January 5, 2018 Trailing in the wake of Pfizer’s Ibrance, Novartis’ Kisqali is one step closer to nabbing a regulatory boost.
Ibrance, Kisqali go to battle in England after twin NICE nods by Carly Helfand Thursday, November 16, 2017 New discount deals with cost watchdogs in England have breast cancer drugs from Pfizer and Novartis on more equal footing than in the U.S.
Novartis' Kisqali finds niche in younger women by Carly Helfand Thursday, November 9, 2017 Novartis breast cancer med Kisqali has struggled to gain traction in a field dominated by Pfizer's Ibrance. So it’s branching out.
Don't count out a consumer spinoff, Pfizer execs say by Carly Helfand Tuesday, October 31, 2017 It didn’t take long for analysts to turn Pfizer's Q3 earnings conversation back to their favorite topic: M&A.
Lilly latecomer Verzenio stands apart in launch's early days by Carly Helfand Monday, October 30, 2017 Lilly's new cancer drug Verzenio faces two tough rivals—Pfizer's Ibrance and Novartis' Kisquali—but the company says it's standing out from the crowd.
